Document Detail


Technetium 99m sestamibi in the assessment of acute myocardial infarction.
MedLine Citation:
PMID:  1835138     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Technetium 99m sestamibi is a promising new radiopharmaceutical that can assess myocardium at risk, infarct size, and treatment efficacy in acute myocardial infarction. The minimal redistribution of this radiopharmaceutical makes it ideal for the measurement of myocardium at risk, as demonstrated by several animal studies. The high-count density images are readily quantitated, and techniques have been developed and validated for this purpose. Early clinical studies have shown that myocardium at risk varies widely, even for a coronary occlusion in a similar location, a finding similar to that reported previously in several different animal infarction models. The clinical use of this radiopharmaceutical to measure final infarct size and treatment benefit, or myocardial salvage, has now been demonstrated using both planar and tomographic imaging techniques. Evidence of benefit is often evident by 18 to 48 hours after reperfusion therapy, although the full extent of improvement is not evident until later. The current 6-hour shelf life and 30-minute preparation time are logistical barriers to widespread clinical use. This radiopharmaceutical provides a new, powerful measurement tool for the assessment of treatment efficacy in acute myocardial infarction that is probably superior to other currently available methods.
Authors:
R J Gibbons
Related Documents :
3941218 - Reverse redistribution of thallium-201: a sign of nontransmural myocardial infarction w...
1627448 - Myocardial perfusion imaging in the diagnosis of coronary artery disease.
1519518 - Identification of viable myocardium by dipyridamole-induced improvement in regional lef...
12691128 - Left ventricular mass index measured by quantitative gated myocardial spect with 99mtc-...
1424028 - Effect of normothermic blood cardioplegia on postoperative conduction abnormalities and...
9337208 - Myocardial 99mtc-tetrofosmin uptake during adenosine-induced vasodilatation with either...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Seminars in nuclear medicine     Volume:  21     ISSN:  0001-2998     ISO Abbreviation:  Semin Nucl Med     Publication Date:  1991 Jul 
Date Detail:
Created Date:  1991-11-27     Completed Date:  1991-11-27     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  1264464     Medline TA:  Semin Nucl Med     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  213-22     Citation Subset:  IM    
Affiliation:
Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, MN 55905.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Heart / radionuclide imaging
Humans
Myocardial Infarction / drug therapy,  radionuclide imaging*
Nitriles / diagnostic use*
Organotechnetium Compounds / diagnostic use*
Technetium Tc 99m Sestamibi
Thrombolytic Therapy
Chemical
Reg. No./Substance:
0/Nitriles; 0/Organotechnetium Compounds; 109581-73-9/Technetium Tc 99m Sestamibi
Comments/Corrections
Comment In:
Semin Nucl Med. 1991 Jul;21(3):170-2   [PMID:  1835135 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Technetium 99m sestamibi in the assessment of chronic coronary artery disease.
Next Document:  Combined treatment (goserelin plus flutamide) versus monotherapy (goserelin alone) in advanced prost...